{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:14:24Z","timestamp":1793884464644,"version":"4.7.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013238","name":"Mahidol University Faculty of Medicine Siriraj Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113480","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T11:59:20Z","timestamp":1730289560000},"page":"113480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"P2","title":["Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-9055","authenticated-orcid":false,"given":"Kamonlapat","family":"Supimon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0612-0981","authenticated-orcid":false,"given":"Thanich","family":"Sangsuwannukul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-1967","authenticated-orcid":false,"given":"Piriya","family":"Luangwattananun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-5927","authenticated-orcid":false,"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2024.113480_b0005","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"J. Am. Med. Assoc."},{"issue":"8","key":"10.1016\/j.intimp.2024.113480_b0010","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113480_b0015","doi-asserted-by":"crossref","first-page":"20705","DOI":"10.1038\/s41598-023-47906-y","article-title":"A population-based study on incidence trends of myeloma in the United States over 2000\u20132020","volume":"13","author":"Mousavi","year":"2023","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2024.113480_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040590","article-title":"Socioeconomic Factors and Survival of Multiple Myeloma Patients","volume":"13","author":"Chamoun","year":"2021","journal-title":"Cancers (basel)"},{"issue":"9","key":"10.1016\/j.intimp.2024.113480_b0025","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.3390\/ijms22094462","article-title":"The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma","volume":"22","author":"Giannakoulas","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113480_b0030","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/232546","article-title":"Implications of heterogeneity in multiple myeloma","volume":"2014","author":"de Mel","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.intimp.2024.113480_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/JEP.S265288","article-title":"Novel Experimental Drugs for Treatment of Multiple Myeloma","volume":"13","author":"Offidani","year":"2021","journal-title":"J. Exp. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113480_b0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.hoc.2023.12.002","article-title":"Monoclonal Antibodies in the Treatment of Multiple Myeloma","volume":"38","author":"van de Donk","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"3","key":"10.1016\/j.intimp.2024.113480_b0045","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson","year":"2022","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113480_b0050","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113480_b0055","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113480_b0060","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2024.113480_b0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.20517\/cdr.2022.138","article-title":"Anti-BCMA novel therapies for multiple myeloma","volume":"6","author":"Sammartano","year":"2023","journal-title":"Cancer Drug Resist."},{"issue":"4","key":"10.1016\/j.intimp.2024.113480_b0070","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.13380","article-title":"B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis","volume":"104","author":"Gagelmann","year":"2020","journal-title":"Eur. J. Haematol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113480_b0075","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.113480_b0080","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-cancerbio-061421-014236","article-title":"Next-Generation Therapies for Multiple Myeloma","volume":"8","author":"Meermeier","year":"2024","journal-title":"Annu Rev Cancer Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113480_b0085","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res."},{"issue":"27","key":"10.1016\/j.intimp.2024.113480_b0090","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.113480_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632937","article-title":"Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma","volume":"12","author":"Jasi\u0144ski","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113480_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.intimp.2024.113480_b0105","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2017.111","article-title":"Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use","volume":"28","author":"Lock","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113480_b0110","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061243","article-title":"Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question","volume":"14","author":"Ord\u00f3\u00f1ez-Reyes","year":"2022","journal-title":"Pharmaceutics."},{"issue":"8","key":"10.1016\/j.intimp.2024.113480_b0115","doi-asserted-by":"crossref","first-page":"e7048","DOI":"10.1002\/cam4.7048","article-title":"Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden","volume":"13","author":"Uttervall","year":"2024","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.113480_b0120","article-title":"Bispecific T-Cell Engagers Therapies in Solid Tumors","volume":"15","author":"Sim\u00e3o","year":"2023","journal-title":"Focusing on Prostate Cancer. Cancers (basel)"},{"issue":"3","key":"10.1016\/j.intimp.2024.113480_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006680","article-title":"Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody","volume":"11","author":"Park","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.113480_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008744","article-title":"Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3\u00d7anti-GD2 bispecific antibody armed T cells","volume":"12","author":"Yankelevich","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.113480_b0135","doi-asserted-by":"crossref","first-page":"1773201","DOI":"10.1080\/2162402X.2020.1773201","article-title":"Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients","volume":"9","author":"Lum","year":"2020","journal-title":"Oncoimmunology."},{"issue":"1","key":"10.1016\/j.intimp.2024.113480_b0140","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/1078-0432.CCR-22-1601","article-title":"Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer","volume":"29","author":"Vaishampayan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.113480_b0145","doi-asserted-by":"crossref","first-page":"e0265773","DOI":"10.1371\/journal.pone.0265773","article-title":"Antitumor activity of T cells secreting \u03b1CD133-\u03b1CD3 bispecific T-cell engager against cholangiocarcinoma","volume":"17","author":"Sangsuwannukul","year":"2022","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.intimp.2024.113480_b0150","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcyt.2022.10.006","article-title":"Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells","volume":"25","author":"Supimon","year":"2023","journal-title":"Cytotherapy"},{"issue":"4","key":"10.1016\/j.intimp.2024.113480_b0155","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.21873\/anticanres.15655","article-title":"Cytotoxic T Cells Activated by Self-differentiated Monocyte-derived Dendritic Cells Against Multiple Myeloma Cells","volume":"42","author":"Wannasiri","year":"2022","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.intimp.2024.113480_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071760","article-title":"MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers (basel)"},{"issue":"Pt B","key":"10.1016\/j.intimp.2024.113480_b0165","article-title":"Anti-PD-L1 \u00d7 anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L1","volume":"124","author":"Luangwattananun","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2024.113480_b0170","doi-asserted-by":"crossref","unstructured":"Rampotas A, Sangha G, Collins GP. Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma. Ther Adv Hematol. 2021;12:20406207211053120.","DOI":"10.1177\/20406207211053120"},{"issue":"14","key":"10.1016\/j.intimp.2024.113480_b0175","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2024.113480_b0180","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2967\/jnumed.120.259036","article-title":"Mesothelin\/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues","volume":"62","author":"Suurs","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.intimp.2024.113480_b0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exphem.2020.07.003","article-title":"Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome","volume":"88","author":"Pabst","year":"2020","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113480_b0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113480_b0195","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V73.7.1925.1925","article-title":"Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow","volume":"73","author":"King","year":"1989","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2024.113480_b0200","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2020.266841","article-title":"BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice","volume":"108","author":"Zhou","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2024.113480_b0205","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1038\/s41467-024-49286-x","article-title":"Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response","volume":"15","author":"Webb","year":"2024","journal-title":"Nat. Commun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:34:09Z","timestamp":1736303649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924020022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"alternative-id":["S1567576924020022"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113480","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113480"}}